Future presentation at the AUA 2012

AUA (American Urological Association) in Atlanta, GA, USA, 19 -23 may 2012.

François Giuliano will present 1 poster:

"Tadalafil 5 mg once daily for lower urinary tract symptoms (luts) secondary to benign prostatic hyperplasia (BPH): a Phase 3, multicenter, double-blind, randomized, placebo- and tamsulosin-controlled trial"
M. Oelke, F. Giuliano, V. Mirone, D. Cox, L. Viktrup.

Pelvipharm will be represented by Delphine Behr-Roussel at the AUA annual meeting.

We warmly invite you to take this opportunity to learn more about our services.
If you’d like to set up a specific meeting at any time throughout the congress, please email staffpelvipharm@pelvipharm.com and we will be happy to discuss our results with you and potential applications for you.

March 19th - 2012

Recently published paper in Archives of Sexual Behavior

Who, What, Where, When (and Maybe Even Why)? How the Experience of Sexual Reward Connects Sexual Desire,Preference, and Performance
Pfaus JG, Kippin T, Coria-Avila G, Gelez H, Afonso V, Ismail N, Parada M.
Arch Sex Behav - 2012 : Mar 9. [Epub ahead of print].

February 10th - 2012

Bio-Europe Spring in Amsterdam, March 2012

Pelvipharm will be represented by Delphine Behr-Roussel at the next BIO-Europe Spring meeting in Amsterdam, March 19-21 2012. We warmly invite you to take this opportunity to learn more about our services.

If you’d like to set up a specific meeting at any time throughout the conference, please email staffpelvipharm@pelvipharm.com and we will be happy to assist you.

March 1st - 2012

Recently published paper in Eur Urol

Minimal Effective Dose of Dysport and Botox in a Rat Model of Neurogenic Detrusor Overactivity.

Behr-Roussel D, Oger S, Pignol B, Pham E, Le Maux A, Chabrier PE, Caisey S, Compagnie S, Picaut P, Bernabé J, Alexandre L, Giuliano F, Denys P.

Eur Urol. 2012 Feb 8. [Epub ahead of print]

January 9th - 2012

Future presentations at the EAU 2012

Pelvipharm at the EAU (European Association of Urology) in Paris, France, 24 - 28 February 2012.

Pelvipharm will present 3 posters:

"Minimal effective dose (MED) of onabotulinumtoxinA (onaBoNT-A) and abobotulinumtoxinA (aboBoNT-A) in a rat model of neurogenic detrusor overactivity (NDO)"
D. Behr-Roussel, S. Oger, B. Pignol, E. Pham, A. Le Maux, P.E. Chabrier, P. Picaut, S. Caisey, S. Compagnie, F. Giuliano, P. Denys.
"Evidence for a functional role of connexin 43 and 45 in human neurogenic detrusor overactivity"
V. Phe, D. Behr-Roussel, S. Oger, E. Chartier-Kastler, T. Ghoneim, T. Lebret, G. Karsenty, E. Comperat, P. Camparo, P. Validire, F. Giuliano.
"Spontaneous contractile activity of human neurogenic bladder strips: Can we predict a correlation with between clinical factors, urodynamics and histological features?"
V. Phe, S. Oger, D. Behr-Roussel, P. Denys, E. Comperat, F. Giuliano, E. Chartier-Kastler.

François Giuliano will present 1 poster:
"Effects of tadalafil (TAD) or tamsulosin (TAM) on erectile function in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): Results from a multicenter, double-blind, randomized, placebo (PLA)-controlled 12-week study"
F. Giuliano; M. Oelke; V. Mirone; S. Watts; D. Cox; L. Viktrup

Delphine Behr-Roussel will chair the session 40 : "Sexual dysfunction: Basic research"

Please come and see us, we will be happy to discuss our results with you and potential applications for you.

January 2nd - 2012

Season's Greetings from the team at PELVIPHARM

We wish for you the very best for the new year, and extend our sincerest gratitude for your interest in our preclinical services.